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Abstract
Agonist-stimulated platelet activation triggers conformational changes of integrin αIIbβ3,
allowing fibrinogen binding and platelet aggregation. We have previously shown that an
octapeptide, p1YMESRADR8, corresponding to amino acids 313–320 of the β-ribbon
extending from the β-propeller domain of αIIb, acts as a potent inhibitor of platelet aggrega-
tion. Here we have performed in silicomodelling analysis of the interaction of this peptide
with αIIbβ3 in its bent and closed (not swing-out) conformation and show that the peptide is
able to act as a substitute for the β-ribbon by forming a clasp restraining the β3 hybrid and βI
domains in a closed conformation. The involvement of species-specific residues of the β3
hybrid domain (E356 and K384) and the β1 domain (E297) as well as an intrapeptide bond
(pE315-pR317) were confirmed as important for this interaction by mutagenesis studies of
αIIbβ3 expressed in CHO cells and native or substituted peptide inhibitory studies on plate-
let functions. Furthermore, NMR data corroborate the above results. Our findings provide
insight into the important functional role of the αIIb β-ribbon in preventing integrin αIIbβ3
head piece opening, and highlight a potential new therapeutic approach to prevent integrin
ligand binding.
Introduction
Integrin αIIbβ3, the platelet fibrinogen and vonWillebrand factor (vWF) receptor, plays a key
role in hemostasis and thrombosis, by promoting platelet aggregation and thrombus formation
at sites of vascular injury. As circulating platelets in blood are constantly exposed to high
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concentrations of fibrinogen, αIIbβ3 ligand binding has to be tightly controlled to prevent
inappropriate thrombus formation. Integrin αIIbβ3 is therefore maintained in a constitutive
low-affinity state, and agonist-induced platelet stimulation is required to convert αIIbβ3 from
a low- to a high-affinity state, able to bind ligands [1].
Unravelling the molecular mechanisms that regulate platelet integrin αIIbβ3 activation has
been the focus of intense research. Initial structural information came from electron micros-
copy (EM) pictures of purified αIIbβ3 showing its particular shape with a globular head piece
connected to two flexible stalks [2]. The 3.1Å crystal structure of the ectodomain of integrin
αvβ3 [3], and later of αIIbβ3 [4, 5], revealed that the ligand-binding globular head piece is com-
posed of the N-terminal part of both α and β subunits, comprising the β-propeller of the α sub-
unit associated to the βI and hybrid domains of the β subunit. The flexible stalks or legs
comprise multiple domains, corresponding to an Ig-like “thigh” and two β-sandwich “calf”
domains for the α subunit, and one PSI, four EGF and one β-tail (βTD) domains for the β sub-
unit. An unexpected initial finding however was the bent, V-shaped conformation of the αvβ3
receptor with a sharp knee-like kink in the middle section of both legs, bringing the headpiece
into intimate contact with the lower leg domains.
On the basis of data obtained from crystal structures of αIIbβ3 [4, 5], epitope mapping with
anti-αIIb, -β3 or -αIIbβ3 antibodies [6, 7], as well as EM and cryo-electron microscopy (cryo-
EM) pictures [8–11], it is now largely accepted that the bent-closed conformation represents
the low-affinity, resting state of αIIbβ3. Integrin affinity upregulation relies on several major
conformational changes, namely integrin extension at the knees, leg separation, and a β3-sub-
unit swing-out motion at the interface between the βI and hybrid domains, converting the
headpiece from a closed to an open conformation, thus facilitating ligand binding by the head-
piece [12, 13].
Experiments based on mutant αIIbβ3 receptor function or LIBS antibody bindings have
shown that the low-affinity state of β3 integrins is stabilized by several clasps, two of which
exist at the transmembrane and cytoplasmic face of the receptor [14–16]. Additional contacts
also exist in multiple points along the α and β extracellular legs [6, 15], which might be
involved in modulating the transition through different conformations between the inactive
and active states of integrins. More importantly however, a clasp in the headpiece, involving
the β-ribbon of the αv β-propeller domain (residues 301–308) or the corresponding αIIb
domain (segment 313–320) appear to play a major role in preventing the swing-out motion of
the β3 hybrid domain [5, 17]. This is consistent with previous suggestions of the existence of
such a clasp in integrin αIIbβ3 [4], together with results from targeted molecular dynamic
(TMD) studies [18]. These results have been confirmed by Kamata et al. by engineering disul-
phide bonds between these regions resulting in inhibition of ligand binding [19], and further
corroborated using new engineered disulphide bond mutant receptors [20]. Also, peptides cor-
responding to the αv or the related αIIb sequence as well as the β3 sequence of this clasp pro-
moted integrin activation [17]. Intriguingly, the reported αIIb peptide (pMESRADRK) almost
completely overlaps with an octapeptide pYMESRADR, previously shown by us to exert an
inhibitory effect on αIIbβ3 integrin function by blocking fibrinogen binding to αIIbβ3 [21, 22].
Considering these apparently contradictory data, we have performed in silico structural model-
ling of our octapeptide with αIIbβ3 in its bent-closed conformation (PDB: 3FCS) and used in
silico as well as experimental data to demonstrate that the αIIb octapeptide, initially thought to
interact with fibrinogen [21], substitutes for the αIIb β-ribbon by establishing interactions with
both the βI and hybrid domain of β3, thus preventing the swing-out motion of the hybrid
domain necessary for head opening and high-affinity ligand binding.
An αIIb Peptide Inhibits αIIbβ3 Activation
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Materials & Methods
Peptide Synthesis
Peptides were synthesized on a Wang resin (0.75 meqg-1 resin) using the standard SPPS meth-
odology [23, 24]. Five octapeptides were synthesized: native peptide pYMESRADR, 3 substi-
tuted peptides pYMESRAAR, pYMESAADR and pYMESRADA and the “shifted” peptide
pMESRADRK.
Structural Modelling and Analysis
Structural modelling and analysis was performed using the program ICM-Pro v.3.7-2a (www.
molsoft.com). All the relevant and available structures were analysed. A combination of super-
imposition and modelling was performed to generate atomic models of the non-existent integ-
rin conformations, assuming that similar motion ranges are shared by close members of the
integrin family. Superimposition was performed (as implemented in ICM) for the domains
forming the headpieces followed by tethering of corresponding atoms from homologous and/
or identical domains. The tether energies were minimised whilst phi/psi torsion angles of resi-
dues found at interdomain hinge regions were made to rotate within allowed regions. Next,
side-chain clashes were solved using local energy minimisation cycles. The remaining clashes
were solved through Monte-Carlo searches followed by local energy minimisation cycles. The
length of the Monte-Carlo searches was defined by the algorithm implemented in ICM.
Platelet Preparation
Venous blood from informed healthy donors was obtained from the French blood bank insti-
tute (EFS) according to the agreement between INSERM and EFS (CPSL C UNT—06/EFS/
029). During the medical examination preceding blood donation, the medical doctor of EFS
informed the healthy donors that part of their blood could be used for research. All blood sam-
ples used in the present study have been provided by healthy donors, which signed the agree-
ment. The samples were anonymized at the EFS prior deliverance to the laboratory. According
to the French law (L1211-2), this research is considered as a non-interventional research that
does not require prior approval of the ethics committee. Blood was collected in Vacutainer
tubes containing ACD-A (citric acid-citrate-glucose) (BD Vacutainer, Becton Dickinson, Le
Pont de Claix, France) and was centrifuged for 12 min at 210g in presence of PGE1 2 x 10−7 M
to obtain platelet-rich plasma (PRP). PRP was diluted with washing buffer (103 mMNaCl, 5
mM KCl, 2 mM CaCl2, 1 mMMgCl2, 5 mM glucose and 36 mM citric acid; pH 6.5) containing
PGE1 2 x 10−7 M and 0.06 U apyrase/ml (Sigma Aldrich, St. Louis, MO, USA), then centrifuged
for 12 min at 1240g to pellet the platelets. This washing step was repeated and the platelets
were finally resuspended at 2.5 x 108 per ml in reaction buffer (10 mMHepes, 140 mMNaCl, 3
mM KCl, 5 mMNaHCO3, 0.5 mMMgCl2, 10 mM glucose and 2 mM CaCl2; pH 7.4).
Flow Cytometry
Flow cytometry experiments were performed using a Becton Dickinson FACSort. Platelets
were preincubated 5 min with either vehicle (NaCl 0.9%), native or substituted octapeptides (1
mM). When indicated, a further incubation was performed in the presence of RGDS (1 mM).
Platelets were activated 10 min with thrombin 2.5 U/ml (Sigma Aldrich, St. Louis, MO, USA).
Then, the samples were diluted 1:10 in reaction buffer and incubated with both fluorescein iso-
thiocyanate (FITC)-conjugated PAC1 antibody (PAC1-FITC from Becton Dickinson, San Jose,
CA, USA) and phycoerythrin (PE)-conjugated anti-CD62P (from Beckman Coulter, Brea, CA,
USA) to measure αIIbβ3 activation and P-selectin expression, respectively. Platelet activation
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induces the secretion of granule contents, consecutively secreted fibrinogen can bind to acti-
vated integrin. Therefore, fibrinogen binding was measured by single-colour flow cytometry
using FITC-conjugated rabbit polyclonal anti-human fibrinogen antibody. Exposure of LIBS
was evaluated performing mAb AP5 binding (generous gift of Dr T. J. Kunicki, The Scripps
Research Institute, La Jolla, CA, USA), and revealed with PE-labelled anti-mAb antibody. In
each experiment, controls were run with the corresponding isotype control. Single intact plate-
let gate was identified on resting sample by their characteristic profile on a right angle scatter
(SSC) and forward angle scatter (FSC) plot. A total of 10,000 platelet events were recorded.
Results were expressed as the mean fluorescence intensity of resting or thrombin-activated
platelets preincubated with or without RGDS and/or octapeptides relative to the basal condi-
tion corresponding to resting platelets preincubated with vehicle.
Aggregation
Washed platelet aggregation was measured with a PAP-8E Biodata optical aggregometer. Plate-
lets were pre-incubated with octapeptide (pYMESRADR, pYMESRAAR or pMESRADRK) (75
to 500 μM) or vehicle for 5 min at 37°C with stirring (1200 rpm). Thrombin was then added
and aggregation was monitored for 5 min as the change in light transmittance. Results are
expressed as the percentage of maximum aggregation ± SEM.
cDNA Constructs, Transfection and Generation of Stable Cell Clones
The cDNAs encoding αIIbR317A/D319A/R320A (αIIb3M) and β3K384A (β31M) were gener-
ated using the Quikchange site-directed mutagenesis method (Agilent Technologies, Santa
Clara, CA, USA) and the pcDNA3.1(-)Neo-αIIbwt and pcDNA3.1(-)Zeo-β3wt as templates.
The nucleotide sequence of the generated mutants was verified by automated sequencing. Chi-
nese hamster ovary (CHO) cell (CRL 9096, American Type Culture Collection, Rockville, MD)
transfections were performed using lipofectAMINE (Life Technologies Europe B.V., Ghent,
Belgium) as previously described [25], and positive transfectants were screened by flow cytom-
etry for cell surface expression of the recombinant mutant αIIbβ3 complex using an αIIbβ3
complex-specific mAb, Pl2-73 (kind gift from Dr Cécile Kaplan, Institut National de la Trans-
fusion Sanguine, Paris, France), and subcloned by limiting dilution to establish stable cell
clones. Finally, we selected the cell clones having a surface expression of the mutant αIIbβ3
receptors comparable to the cell clone expressing the wild type receptor (S1 Fig).
CHOCell Adhesion
Cell adhesion was performed using flow conditions and real-time video microscopy as previ-
ously described [26]. Briefly, glass coverslips were precoated with 10 μg/ml fibrinogen (from
Dako, Glostrup, Denmark), purified and depleted of contaminant fibronectin and vWF, and
mounted onto a flow chamber of 200 μm height filled with IMDM. CHO cells resuspended in
IMDM at a concentration of 1.25x106/ml were perfused over a fibrinogen-coated coverslip at
flow rates from 60–200 μl/min to produce wall shear rates from 30–100 s-1. In some experi-
ments, cells were preincubated 20 min with 250–500 μM pYMESRADR or pYMESRAAR pep-
tides before perfusion at 30 s-1. Cells were visualized using a 10x Hoffman Modulation
Contrast objective together with an inverted microscope. Real-time images were recorded
using a charged-coupled-device camera. The number of adherent cells was counted over a 12
min time course using Histolab and Archimed software (Microvision Instruments, Evry,
France).
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Statistical Analysis
Results are expressed as mean ± SEM. Differences between samples incubated with vehicle and
with peptides were assessed with Wilcoxon test. Cell adhesion mediated by αIIb3Mβ3, αIIbβ31M
or αIIbβ3 WT was compared with Mann-Whitney test (Prism 4.0, GraphPad Software).
Degrees of statistical significance are defined as P<0.05, P<0.01 and P<0.001.
Results
Analysis of integrin αIIb β-ribbon residues involved in the clasp
preventing αIIbβ3 opening
The octapeptide pYMESRADR derived from integrin αIIb, previously shown to inhibit platelet
aggregation by blocking fibrinogen binding to activated αIIbβ3 [27], corresponds to residues
313–320 of the insert loop (β-ribbon), that extends between the β2 and β3 strands of the W5
blade of the αIIb β-propeller domain [5]. The crystal structure of the bent-closed β3 subunit
conformation tightly accommodates this loop in a cleft formed between the βI, hybrid and the
third and fourth I-EGF domains of β3. Within the loop, three continuous charged residues
establish salt-bridges: E315(αIIb)-R317(αIIb), R320(αIIb)-E297(β3), K321(αIIb)-E356(β3).
Also, the carbonyl group of the peptide bond between A318 and D319 (αIIb) from the β-ribbon
was seen interacting with K384(β3) (Fig 1).
It is worth mentioning that there are several additional inter-domain interactions between
the two integrin subunits outside the region covered by the β-propeller W5 blade loop. One of
such interactions, between Y353(αIIb) and E297(β3) positioned in close vicinity of the β-rib-
bon can be found in αIIbβ3 crystal structures (PDBs 3FCS, 3FCU, 2VDO, 2VDL, 2VDM,
2VDN, 2VDP, 2VDQ, 2VDR, 2VC2, 2VDK).
Alignment of αIIb from several species shows that the β-propeller W5 blade loop is highly
conserved, except for R320, which is substituted by histidine in pig and rabbit. It is noteworthy
that residues K321 and Y353 are absolutely conserved in all the species included in the analysis
(Fig 2A upper alignment) and that the loop is one of the most conserved regions outside the
core β-propeller domain, contrasting with the variability seen elsewhere in this domain, and
underlining its putative role as a molecular latch.
Similarly, the bent-closed conformation adopted by β3 also revealed a highly conserved sur-
face across 13 species (Fig 2B upper alignment), which coincides with the interfacing region of
αIIb and including the β-propeller W5 blade loop. When analysed against homologues, the
level of conservation is rather low for the residues implicated in the W5 blade loop (in αIIb)
and their counterpart interacting residues found in β3 (Fig 2A–2B lower alignments). This can
be interpreted as a result of integrin evolution to diversify the combination between different
partnering α and β subunits acquiring novel roles and functions as a consequence.
Modeling of the interaction of the octapeptide with β3 subunit
In order to explain the inhibitory effect of the pY313MESRADR320 octapeptide on integrin
αIIbβ3 activation, we have performed structural modelling to determine how the octapeptide
could replace the β-ribbon in restraining the β3 chain in its bent-closed conformation. We
have performed in silico searches to assess whether a feasible conformation can be achieved,
whilst observing the anchoring points used by the octapeptide, derived from the native interac-
tions made by the hairpin. We have inspected the possible solutions and identified the most
plausible conformation. In the in silico model of the octapeptide, the aforementioned residues
involved in salt bridges from β3 are maintained, however these are now formed between the
peptide and the hybrid domain (namely pD319(octapeptide)-K384(β3) and pR320
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(octapeptide)-E356(β3)). Interestingly the intrapeptide salt bridge between pE315-pR317 is
maintained, despite changes in the backbone geometry. More importantly, this geometry now
allows a new interaction to be formed between pY313 (octapeptide) and E297(β3), completing
the restraining of the βI + hybrid domains to the geometry found in the bent-closed conforma-
tion (Fig 3).
Interaction of the octapeptide with the β3 subunit of platelet integrin
αIIbβ3
To further test the hypothesis that the octapeptide inhibits platelet activation by direct interac-
tion with the β3 subunit, we investigated its ability to induce the exposure of LIBS (ligand-
induced binding site) neo-epitopes on β3. LIBS epitopes were initially identified on αIIbβ3 fol-
lowing binding of peptide antagonists, such as RGDS, or certain antibodies [28] and are con-
sidered as markers of multiple conformational changes of αIIbβ3 that occur during the
transition of αIIbβ3 from its unliganded-closed to liganded-open conformation [7]. Binding of
the β3-specific AP5 LIBS antibody [29] was monitored by flow cytometry. The native octapep-
tide (Fig 4A) promoted AP5 antibody binding on resting platelets although to a lesser extent
than RGDS did, whereas it was as powerful as RGDS to induce AP5 binding on thrombin-acti-
vated platelets. Co-treatment with pY313MESRADR320 and RGDS did not result in a synergistic
effect to induce further AP5 binding. Similar results were also obtained with another β3-spe-
cific LIBS antibody, LIBS1, (S2 Fig). Moreover, similarly to RGDS, the octapeptide inhibited
Fig 1. The β-ribbon YMESRADR sequence clasps αIIb to β3 in the bent-closed conformation. [LEFT] Two β3 subunit conformations have been
observed in different crystal structures: bent-closed (green) (as seen in the structure of αIIbβ3—3FCS) and extended-open (purple) (as seen in the structure
of αIIbβ3—1TY3/2VDK) while the αIIb β-propeller (yellow) position remains unchanged. The latch hairpin (blue, YMESRADRmotif) is shown in the structure
of the αIIb β-propeller; [RIGHT] Detail of the αIIb latch hairpin interaction with the bent-closed β3 (3FCS). The αIIb β-propeller domain (yellow) containing the
β-ribbon and the YMESRADRmotif (blue) engages the β3 hybrid domain (green). Two salt-bridges are established across the domains αIIb and β3: R320
(αIIb)-E297(βI domain from β3) and K321(αIIb)-E356(hybrid domain from β3). An additional salt-bridge can be observed within the β-ribbon E315(αIIb)-R317
(αIIb). In the same vicinity the αIIb β-propeller further engages with the β3 βI-domain through Y353(αIIb)-E297(β3). The interactions indicated above suggest
that this region of the αIIb β-propeller plays a role in enforcing the positioning of the βI and hybrid domains when β3 is in its bent-closed conformation. The
YMESRADR residues are shown as sticks with the carbon atoms coloured cyan, oxygen in red and nitrogen in blue. Residues from β3 involved in inter-
subunit interactions are shown as sticks with white carbon atoms.
doi:10.1371/journal.pone.0134952.g001
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fibrinogen binding (Fig 4B left), as well as the binding of PAC1 (Fig 4B middle and Fig 4D), an
antibody that specifically recognizes activated αIIbβ3. This binding did not significantly affect
platelet secretion, as shown by the absence of any effect on CD62P expression on thrombin-
activated platelets (Fig 4B right). These results suggest that the octapeptide does not interact
with fibrinogen but inhibits the activation of integrin αIIbβ3. The inhibitory effect of the pep-
tide was also tested in light-transmission aggregometry under stirring conditions and the
results show that pY313MESRADR320 inhibited platelet aggregation in a concentration-depen-
dent manner (Fig 4C black line).
Fig 2. Amino acid sequence alignments. (A) Sequence alignments of the region surrounding amino acids 320, 321 and 353 from the human integrin αIIb
subunit and αIIb from other species (upper sequences) or with other human α subunits (lower sequences); (B) Sequence alignments of the regions
surrounding amino acids 297, 356 and 384 from the human integrin β3 subunit and β3 from other species (upper sequences) or with other human β subunits
(lower sequences). Conserved residues between human αIIb or β3 and other sequences are shown with light shading.
doi:10.1371/journal.pone.0134952.g002
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In order to further validate our model, experiments were designed using variants of the
octapeptide in which putative residues interacting with β3 were substituted. The importance of
residues pR317, corresponding to the αIIb amino acid involved in intrapeptide salt bridge
R317-E315 (Fig 3), and pD319, was demonstrated by the loss of activity of pR317A or pD319A
substituted octapeptides when tested by measuring AP5 binding (Fig 4A), platelet aggregation
(Fig 4C grey line) and PAC1 binding (Fig 4D). In contrast, pR320A decreased only partially the
ability of the peptide to induce AP5 binding (Fig 4A), and consequently, decreased only faintly
the peptide inhibitory activity on PAC1 binding (Fig 4D). Similar results were obtained with
thrombin-induced fibrinogen binding to platelets (S3 Fig). Finally, we performed aggregation
with an octapeptide shifted by one amino acid (pM314ESRADRK321), which, even at 500 μM,
did not inhibit platelet aggregation (Fig 4C dashed line). This result shows that amino acid
pY313 is essential for the inhibitory activity of the octapeptide.
Fig 3. Model of the interaction of the pYMESRADR peptide with the β3 subunit. Conformation adopted by the pYMESRADR peptide to bridge across the
βI and hybrid domains of β3. Note that residue pY313 from the peptide (corresponding to the Y313 from the native hairpin) now replaces Y353 (cf. Fig 1) in
interacting with the βI domain. The pE315- pR317 intrapeptide salt bridge is also depicted.
doi:10.1371/journal.pone.0134952.g003
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The importance of pY313 for the inhibitory activity of the octapeptide is in line with our
modelling results, where pY313 plays a crucial role in bridging the β-propeller domain across
to the βI + hybrid domains. However this requires the octapeptide to adopt a stable conforma-
tion in solution similar to the one found in our in silicomodelling.
We then revisited our data from a previous NMR structural and functional characterisation
of the native octapeptide and its alanine scanning substitutions [27]. Upon examination of the
solution conformational ensembles, it was clear that the backbone conformation of the native
peptide in solution was being stabilized via an intra-molecular salt-bridge formed by pR317
and pD319 (Fig 5A). However, more interesting are the NMR data of the peptide with the Ala-
nine substitution at position pD319. Indeed, this substitution induced a new backbone
Fig 4. Effect of octapeptides on platelet activation.Washed platelets (2.5x108 platelets/ml) were preincubated with vehicle (NaCl 0.9%) or various
peptides (A, B and D: 500 μM) for 5 min. Platelets were then treated with 0.1 U/ml thrombin (activated) or vehicle (resting) as described in “Experimental
Procedures”. (A) LIBS (AP5 mAb) expression induced by vehicle, RGDS, pYMESRADR, RGDS + pYMESRADR, 317-substituted octapeptide
(pY313MESAADR320), 319-substituted octapeptide (pY313MESRAAR320) or 320-substituted octapeptide (pY313MESRADA320) on resting or thrombin-
activated platelets. AP5 binding was quantified by determining the fluorescence intensity (Geomean UA) of anti-mAb-phycoerythrin binding (n = 6;
mean ± SEM). Isotype control binding (NI, first column) was performed in each experiment; (B) Flow cytometry analysis of anti-fibrinogen-FITC, PAC1-FITC,
anti-CD62P-PE or isotype control (dashed black lines) antibody binding on resting (black lines) or activated platelets preincubated with vehicle (green lines),
pYMESRADR octapeptide (red lines), or RGDS (blue lines); (C) Inhibitory effects of octapeptides (pY313MESRADR320: black; substituted
pY313MESRAAR320: grey or pM314ESRADRK321: dashed) on human washed platelet aggregation induced by thrombin (0.1 U/ml). Platelets were
preincubated with vehicle (peptide 0 μM) or various concentrations of octapeptides and stimulated with thrombin for 5 min. Aggregation is expressed as a
percentage of maximal light transmission measured at 5 min. Each point represents the mean (± SEM) of at least 4 experiments, *P<0.05, **P<0.01, ***P<
0,001 versus untreated platelets (peptide 0 μM); (D)Mean fluorescence intensity of PAC1-FITC binding on thrombin-activated platelets preincubated with
vehicle, RGDS, pYMESRADR or with 317 substituted octapeptide (pYMESAADR), 319 substituted octapeptide (pYMESRAAR) or 320 substituted
octapeptide (pYMESRADA).
doi:10.1371/journal.pone.0134952.g004
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conformation with a change of the intra-molecular salt-bridge from pR317- pD319 to pR317-
pE315 (Fig 5B), almost identical to the conformation of the native octapeptide in our in silico
model (Fig 3). This might be rationalised through the fact that most frequently a peptide will
rearrange its solution conformation to a different allosteric conformation upon binding/inter-
acting with another macromolecule. The NMR data thus suggest that when residue pD319 is
engaged, possibly towards forming the first interaction between the octapeptide and K384
Fig 5. Free solution structures of octapeptides compared to the in silicomodel of pYMESRADR in its inhibitory conformation. (A) Solution structure
of native octapeptide pYMESRADR determined by NMR; (B) In silicomodel of the octapeptide in its inhibitory conformation shown as sticks (as seen in Fig 3)
compared to the NMR ensemble of models of the pD319A substituted octapeptide shown as grey wires. Note that the intra-peptide salt-bridge between
residues pE315- pR317 is present in both structures.
doi:10.1371/journal.pone.0134952.g005
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from the β3 subunit, it frees up the intramolecular interaction with R317, which then can
engage E315 to compensate for the change (Fig 3) resulting in a more stable conformation of
the peptide, in line with our in silicomodel (Fig 5B and Fig 3). This is furthermore reinforced
by the fact that the inhibitory activity of the substituted pD319A octapeptide was only 9%.
Once in such stable conformation, pY313 ends up unexpectedly well-placed to form an
interaction with the β3 headpiece E297 residue, effectively restricting to a certain degree both
the swing-out and extension movements (Fig 3).
Mutations of either αIIb or β3 amino acids involved in the clasp result in
an increased activity state of recombinant integrin αIIbβ3
We generated cell clones expressing αIIbβ3 with mutations in either αIIb or β3. In the cell
clone αIIb3Mβ3, the αIIb subunit had a triple mutation R317A+D319A+R320A, which corre-
sponds to the pRADR sequence considered to be the most crucial for the expression of the
inhibitory activity [22]. The mutant αIIb was co-expressed with wild type β3 in CHO cells,
while in the cell clone αIIbβ31M, the β3 subunit had a single K384A mutation and was co-
expressed with wild type αIIb. Residue K384 in the αΙΙbβ3 crystal structure is indeed at a favor-
able distance to form salt bridges with αIIb (Fig 1).
It has been established that shear forces can increase the sensitivity of integrin αIIbβ3 adhe-
sive interactions as demonstrated by the shear-dependent increase of adhesion of CHO cells
expressing the PlA2 polymorphism of αIIbβ3 [30] and that αIIbβ3 activation is associated with
a stabilization of integrin binding to fibrinogen under shear conditions between 30 s-1 and 100
s-1 [26]. In the present setting, we have demonstrated, as in previous work [26], that increasing
shear rates results in decreased cell adhesion mediated by αIIbβ3. Interestingly, cells expressing
the mutant integrins exhibited increased adhesion as compared to cells expressing wild type
αIIbβ3. Notably, at 100 s-1, only cell clone αIIbβ31M showed residual adhesion. As the receptors
displayed similar density and accessibility on the cell surface (S1 Fig), the differences in cell
adhesion under shear relate most likely to a different activation state of the αIIbβ3 receptor
expressed on the cell surface (Fig 6).
In addition, CHO cell adhesion at the lowest shear rate was determined in the presence of
the octapeptide. The pY313MESRADR320 native octapeptide strongly impaired adhesion of
CHO cells expressing wild type αIIbβ3 or mutated αIIb3Mβ3 with a statistically significant
effect observed at 500 μM, while the pY313MESRAAR320 substituted octapeptide had no effect
(Fig 6B). In contrast, native pY313MESRADR320 was not able to inhibit αIIbβ31M CHO cell
adhesion onto fibrinogen under shear stress. These results demonstrate that (i) the mutation of
αIIb does not impact the binding of the peptide to the integrin in contrast to the β3K384A
mutation (αIIbβ31M) and (ii) the residue
pD319 in the octapeptide plays a crucial role in the
binding of the octapeptide to integrin αIIbβ3.
Discussion
The aim of our study was to rationalise a model that explains the inhibitory effect on integrin
αIIbβ3 activation by the pY313MESRADR320, an octapeptide which corresponds to αIIb β-rib-
bon sequence [4, 5, 18, 22]. Analysis of our in silico data have led us to propose a model in
which the octapeptide substitutes the αIIb β-ribbon in restraining β3 in its closed conforma-
tion, by bridging the βI domain and the hybrid domain of the β3 subunit. This model was then
used to guide the design of our experimental methodology.
The proposed model is supported by following experimental data: (i) the octapeptide inhib-
its platelet aggregation, fibrinogen and PAC1 binding to activated platelets; (ii) alanine replace-
ment or deletion of the amino acids of the octapeptide underline the importance of pD319,
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pR317, pR320, as well as pY313 for the inhibitory activity of the peptide. The unexpected
involvement of pY313 may explain the apparent contradictory results with the shifted peptide
pM314ESRADRK321 which was suggested to activate platelets [17]; and finally, (iii) the octapep-
tide strongly impairs adhesion onto fibrinogen under flow of CHO cells expressing either the
wild type receptor or the receptor with mutations in the αIIb β-ribbon. Additionally, the octa-
peptide is unable to inhibit adhesion of CHO cells expressing the β3K384A mutant, demon-
strating the role played by the salt bridge between pD319-K384(β3) in the octapeptide's
inhibitory activity.
It is also interesting to note that the heptapeptide LSARLAF, which was designed to bind to
residues 315–321 of αIIb activates αIIbβ3 by directly inducing a conformational change in the
receptor [31]. Again, this result agrees with our model, with the LSARLAF playing the opposite
role of the pYMESRADR peptide. Indeed, by binding to the region in αIIb, which encompasses
the β-ribbon, LSARLAF disrupts the interaction between the β-ribbon of αIIb and the hybrid
domain of the β3 subunit, thus facilitating its extension. It is likely that full integrin activation
by LSARLAF also requires an additional inside-out signalling pathway, as suggested by the
study of Pearce et al [32].
Taken together, our results indicate that the pY313MESRADR320 octapeptide exerts its inhib-
itory effect on fibrinogen binding through (i) the establishment of ionic bonds with the β3 sub-
unit, involving residues K384 and E356 from the β3 hybrid domain, and (ii) interaction with
E297 from the β3 I-like domain, thus bridging and stabilizing the αIIbβ3 headpiece in the
closed conformation (Fig 7). This is consistent with the multi-step activation model as pro-
posed by Zhu et al. which depicts the process through eight distinct stages [33]. Transition
from bent-closed to extended-closed steps occurs without major changes in the integrin αIIbβ3
headpiece. This is followed by opening (swing-out) movement from extended-closed step to
Fig 6. CHO cell adhesion to fibrinogen in flow conditions. CHO cells expressing αIIbβ3 wild type (WT
αIIbβ3), mutated on αIIb (αIIb3Mβ3) or on β3 (αIIbβ31M) were perfused over fibrinogen (A) at increasing shear
rates (30 s-1, 50 s-1, 75 s-1 or 100 s-1) or (B) were preincubated 20 min with vehicle (0), 250 μM or 500 μM
pYMESRADR peptide, or substituted control peptide (pYMESRAAR) and then perfused at a shear rate of 30
s-1. Adherent cells were counted after 12 min exposure to shear. (A) Results are expressed as the number of
adherent cells/field, obtained by counting 10 fields. Bars represent mean values and the interquartile range of
at least 3 experiments. (B) Adhesion of WT (left panel), αIIb3Mβ3 (middle panel) and αIIbβ31M (right panel)
cells in the presence of peptides or vehicle was quantified (as described in methods section). The results are
expressed as percentage of adhesion of each clone in presence of peptides relatively to corresponding cells
in presence of vehicle (0) normalized to 100%. (n = 6; mean ± SEM). *P<0.05, **P<0.01
doi:10.1371/journal.pone.0134952.g006
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Fig 7. (A) Integrin extensionmodel and structural rationalisation of inhibition of αIIbβ3 activation by octapeptide pYMESRADR. For clarity only
selected domains of the αIIb and β3 subunits are shown. (I) αIIbβ3 in the initial bent-closed conformation, the β-ribbon is highlighted in the red circle. (II) initial
release of the β-ribbon, to be followed by opening of integrin αIIbβ3 (IV). However, if the octapeptide is present (III), it will then substitute the β-ribbon in
restraining βI (blue) and hybrid (green) domains, impeding opening and therefore preventing full activation of the integrin; (B) Schematic representation of
αIIbβ3 clasp interactions and the binding positions of the pYMESRADR octapeptide. In the physiological clasp the β-ribbon and residue Y353 in the β-
propeller domain (yellow) are linked to the β3 hybrid domain (green) and the βI domain (blue) concomitantly. When the physiological clasp is released, the
octapeptide (red) can then engage with the available anchoring points to reestablish the restraint between the βI (blue) and the hybrid (green) domains. Note
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extended-open step, which eventually leads to activation. In the swinging-out stage however,
during the disengagement of the β-ribbon all the main interaction residues from β3 –namely
E297, E356 and K384 become available for binding by the octapeptide, leading to locking of the
hybrid and βI domains into an intermediate step resembling the extended-closed conformation
(Fig 7)–thus precluding full activation of integrin αIIbβ3.
In fact, this intermediate conformation captured by the binding of the octapeptide might
explain our AP5 antibody binding results. Indeed, AP5 has been reported to only bind to
αIIbβ3 in its activated state. In our scenario, αIIbβ3 already exposes epitopes recognised by
AP5, albeit it is still in an inactive conformation. This is further reinforced by a similar observa-
tion made by Cheng et al. where a disulphide bond, which was engineered to perform a similar
structural role as the one we believe the octapeptide is playing, does not completely inhibit the
binding of AP5 induced by Kistrin (a small RGD-containing protein) [20].
However, and given that the octapeptide contains a RAD sequence, one might assume that
this sequence could compete with the binding site of the integrin for the RGD domain of fibrin-
ogen. On the other hand, our previous evidence that the octapeptide inhibited rabbit platelet
aggregation ex vivo and in vivo, in fact strongly supports a non-RGD like mechanism of inhibi-
tion [34]. Indeed, rabbit platelets have previously been used as a suitable thrombosis model for
testing the efficacy of peptides unrelated to RGD, since RGD is inactive on rabbit platelet aggre-
gation and fails to displace fibrinogen from their surface [35, 36]. Moreover, it has been previ-
ously demonstrated that RAD peptides do not exhibit any activity and are used as negative
controls [37–39]. These are strong arguments, although not definitive, that the octapeptide is
probably not interacting with the RGD binding site of the integrin.
In conclusion, our data and those of the literature highlight the important role of the αIIb β-
ribbon in maintaining the closed inactive conformation of αIIbβ3 by securing the hinge angle
between the βI and the hybrid domain. This precludes conformational changes necessary for
the extension of integrin αIIbβ3 to its high-affinity ligand-binding state. The results of the pres-
ent study lend further support to the above assumption by presenting detailed interactions
between residues, and especially by emphasizing the role of Y353(αIIb) in bridging the hybrid
domain of β3 with the βI domains of β3. Finally, an allosteric inhibition of αIIbβ3, induced by
the octapeptide, may provide an alternative pharmacological approach to the αIIbβ3 RGD-like
antagonists. Such allosteric antagonists could reduce the risk of paradoxical receptor activation
observed with the cooperative fibrinogen inhibitors [40, 41].
Supporting Information
S1 Fig. Flow cytometry analysis of αIIbβ3 expression in transfected CHO cells. CHO cells
expressing the αIIbβ3 wild-type receptor (blue line), the αIIb3Mβ3 mutant (αIIbR317A/D319A/
R320A-β3) (green line) or the αIIbβ31M (αIIb-β3K384A) (red line) were labeled with saturating
amounts of anti-αIIb-PE antibody. The isotype control is shown as the thin black line.
(PDF)
S2 Fig. Binding of LIBS1 antibody to platelets. LIBS1 or control antibody (NI) binding on
resting or thrombin-activated platelets pre-incubated with vehicle, RGDS or pYMESRADR
peptides. Bound LIBS1 was revealed with PE- anti-mAb antibody and quantified on Becton
Dickinson FACSort cytometer.
(PDF)
that the octapeptide (red) is stabilized through different intra-peptide salt-bridges (orange lines): pR317- pD319 when in solution, and pR317- pE315 when
bridging across the βI (blue) and the hybrid (green) domain. The numbering of the residues is shown in the blue callout boxes.
doi:10.1371/journal.pone.0134952.g007
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S3 Fig. Effect of octapeptides on fibrinogen-binding to platelets.Washed platelets (2.5x108
platelets/ml) were preincubated with vehicle (NaCl 0.9%), RGDS, pYMESRADR or with
317-substituted octapeptide (pYMESAADR), 319-substituted octapeptide (pYMESRAAR) or
320-substituted octapeptide (pYMESRADA) (500 μM) for 5 min. Platelets were then treated
with 0.1 U/ml thrombin and fibrinogen-binding was measured by single-colour flow cytometry
using a FITC-labeled rabbit anti-fibrinogen antibody. Results are expressed as mean fluores-
cence intensity of at least 3 experiments +/- SEM.
(PDF)
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